Table 2 Distribution of the patients in accordance with decision to perform TEE, with demographic data, thromboembolic and bleeding risk stratification, echocardiography findings and concomitant disease
TEE performed (n, %) | TEE not performed (n, %) | |
|---|---|---|
Male | 77 (64.2%) | 200 (64.1%) |
Female | 43 (35.8%) | 112 (35.9%) |
On warfarin | 71 (23.2%) | 235 (76.8%) |
On NOACs | 49 (38.9%) | 77 (61.1%) |
Mean age, years ± SD | 63.5 ± 11.1 | 65.2 ± 11.6 |
CHA2DS2-VASc value ± SD | 3.5 ± 1.5 | 3.6 ± 1.6 |
HAS-BLED value ± SD | 1.1 ± 1.0 | 1.0 ± 0.8 |
HF | 98 (81.7%) | 232 (74.4%) |
AH | 113 (94.2%) | 288 (91.7%) |
CAD | 54 (45.0%) | 162 (51.9%) |
Previous stroke or TIA | 8 (6.7%) | 15 (4.8%) |
DM | 16 (13.3%) | 38 (12.2%) |
BMI <25 kg/m2 | 13 (11.1%) | 47 (16.2%) |
BMI 25,0 – 29,9 kg/m2 | 47 (40.2%) | 91 (31.4%) |
BMI ≥30 kg/m2 | 60 (49.6%) | 152 (52.4%) |
LVH | 7 (5.8%) | 22 (7.1%) |
LVEF ≥50% | 59 (49.2%) | 160 (51.3%) |
LVEF 41-49% | 33 (27.5%) | 105 (33.7%) |
LVEF ≤40% | 28 (23.3%) | 47 (15.1%) |
No LA enlargement | 19 (15.8%) | 54 (17.3%) |
I° LA enlargement | 24 (20.0%) | 102 (32.7%) |
II° LA enlargement | 38 (31.7%) | 88 (28.2%) |
III° LA enlargement | 39 (32.5%) | 68 (21.8%) |
Total | 120 (27.8%) | 312 (72.2%) |